Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Inactive
Last updated: May 29, 2025
Biosynthetic Calcium Injectable Implant

"Inject and Forget" Contraceptive Drug Delivery Device

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Undetermined
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): Murdoch University
Active
Last updated: May 29, 2025
Biodegradable Implant with [Poly(PDL-co-DO)] Co-Polymers

LNG Biodegradable Implant, Yale BDI

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Yale University, FHI 360
Active
Last updated: May 1, 2025
Mturituri Herbal Contraceptive

Abrus Precatorius or Commiphora Africana

  • User: Female/Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Kenya Institute of Primate Research
Active
Last updated: May 1, 2025
UniPron
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Kenya Institute of Primate Research
Active
Last updated: April 30, 2025
Ultra-Long-Acting MPT In-Situ Forming Implant

ISFI

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of North Carolina
Active
Last updated: April 29, 2025
Antiviral Peptide + Nonhormonal Contraceptive IVR
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Oak Crest Institute of Science
Active
Last updated: April 29, 2025
Injectable Porous Silicon Microparticles
  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): University of California San Diego, FHI 360
Active
Last updated: April 17, 2025
Herbal Bioactive Spermicide
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Vaginal Gel
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Lagos
Inactive
Last updated: April 17, 2025
Lower-Dose DMPA

Depo-Provera 45 mg, Depo-Provera 75 mg

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): FHI 360
Active
Last updated: April 17, 2025
DMPA SI

TV-46046

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Injectable
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Teva, FHI 360